Dolutegravir for COVID-19: real-time analysis of 2 studies

Dolutegravir for COVID-19

2 studies with >1,000 patients

Control

Dolutegravir Serious Outcome Risk

No significant improvements are seen in meta analysis to date.

COVID-19 Dolutegravir studies. Dec 2025. c19early.org


Jun 26 2024	Abbaspour Kasgari et al., BioImpacts, doi:10.34172/bi.29952	Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial
	202% higher mortality (p=0.49) and 5% lower need for oxygen therapy (p=1). RCT 93 hospitalized patients with moderate COVID-19 showing no significant difference in clinical outcomes with dolutegravir treatment compared to placebo.
Apr 13 2023	Verburgh et al., AIDS, doi:10.1097/QAD.0000000000003577	No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands
	14% higher combined mortality/hospitalization (p=0.54) and 20% more cases (p=0.75). Analysis of two Dutch cohorts with HIV showing no association between tenofovir disoproxil fumarate (TDF), etravirine (ETR), or integrase-strand transfer inhibitors (INSTIs) use and either the risk of incident SARS-CoV-2 infection or seve..